Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026

The glucagon-like peptide (glp)-1 agonists weight loss drugs market size has grown rapidly in recent years. It will grow from $15.5 billion in 2025 to $18.02 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to rising obesity prevalence, diabetes drug innovation, lifestyle disease burden, early glp-1 diabetes use, healthcare awareness campaigns.

The glucagon-like peptide (glp)-1 agonists weight loss drugs market size is expected to see rapid growth in the next few years. It will grow to $32.87 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to approval of new glp-1 drugs, expansion of obesity clinics, increased insurance coverage, long-term weight management focus, rising global obesity rates. Major trends in the forecast period include rising demand for pharmacological weight management, increased use of injectable weight loss drugs, growing adoption of glp-1 therapies beyond diabetes, expansion of obesity treatment programs, improved patient adherence to long-term therapy.

The rising prevalence of obesity is expected to drive the growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market in the coming years. Obesity is a medical condition marked by excessive body fat accumulation that poses health risks. Increasing obesity rates are largely due to unhealthy dietary habits, including high consumption of fast food and sugary beverages, combined with poor nutritional balance. As more individuals experience obesity and related health complications, the demand for effective treatment options is growing, thereby boosting the use of GLP-1 agonist weight loss drugs for their demonstrated ability to support weight reduction and improve metabolic health. For instance, in May 2025, the Office for Health Improvement and Disparities, a UK-based government body, reported that between 2023 and 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64% in 2022-2023. Therefore, the increasing prevalence of obesity is fueling the growth of the GLP-1 agonist weight loss drugs market.

Key companies in the GLP-1 agonist weight loss drugs market are focusing on developing innovative therapies to enhance obesity treatment efficacy and improve patient outcomes. These obesity treatment solutions involve therapies that mimic the GLP-1 hormone to regulate appetite, increase satiety, and promote weight loss. They help manage obesity by supporting metabolic function and long-term weight control. For example, in November 2023, Eli Lilly and Company, a US-based pharmaceutical firm, received FDA approval for Zepbound, a drug for chronic weight management in adults with obesity or overweight who have related health conditions such as type 2 diabetes or sleep apnea. The medication works by activating GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic performance.

In December 2023, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics for $2.7 billion. Through this acquisition, Roche obtained access to Carmot's pipeline of incretin-based therapies for obesity and diabetes, including dual GLP-1/GIP receptor agonists CT-388 and CT-868, as well as GLP-1 receptor agonist CT-996. Carmot Therapeutics Inc., a US-based biotechnology company, focuses on developing disease-modifying therapies for metabolic conditions such as obesity and diabetes.

Major companies operating in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2025. The regions covered in the glucagon-like peptide (glp)-1 agonists weight loss drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glucagon-like peptide (glp)-1 agonists weight loss drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the glucagon-like peptide (glp)-1 agonists weight loss drugs market by increasing costs of imported active pharmaceutical ingredients and injectable drug devices. Hospitals and retail pharmacies are most affected due to reliance on imported formulations. These tariffs increase drug prices by raising production and distribution costs for injectable weight management therapies. However, they support domestic pharmaceutical manufacturing, encouraging local API production and formulation of GLP-1 agonists.

The glucagon-like peptide (glp)-1 agonists weight loss drugs market research report is one of a series of new reports that provides glucagon-like peptide (glp)-1 agonists weight loss drugs market statistics, including glucagon-like peptide (glp)-1 agonists weight loss drugs industry global market size, regional shares, competitors with a glucagon-like peptide (glp)-1 agonists weight loss drugs market share, detailed glucagon-like peptide (glp)-1 agonists weight loss drugs market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide (glp)-1 agonists weight loss drugs industry. This glucagon-like peptide (glp)-1 agonists weight loss drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glucagon-like peptide (GLP)-1 agonists are medications that mimic the effects of the GLP-1 hormone to help regulate blood sugar levels and reduce appetite. They enhance insulin secretion, slow gastric emptying, and promote a sense of fullness. While originally developed for type 2 diabetes, they are now widely used for weight management in overweight and obese individuals.

The main drugs in the glucagon-like peptide (GLP)-1 agonists weight loss market include semaglutide, liraglutide, tirzepatide, and others. Semaglutide, marketed as Wegovy, is an injectable prescription medication intended to support weight loss in adults with obesity or overweight conditions accompanied by weight-related health issues. These drugs are administered via parenteral or oral routes and are distributed through hospital pharmacies, retail pharmacies, and other pharmacy channels.

The glucagon-like peptide (GLP)-1 agonists weight loss drugs market consists of sales of products such as dulaglutide (trulicity), exenatide (byetta, bydureon), and lixisenatide (adlyxin). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.